{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:05:47Z","timestamp":1789211147211,"version":"build-2803163510"},"reference-count":57,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,8,13]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Checkpoint blockade (CPB) has limited efficacy in patients with colorectal cancer (CRC), warranting improved therapeutic strategies capable of remodeling the tumor microenvironment. Stem-like TCF1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, cytotoxic CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, and lymphoid aggregates have been associated with CPB responsiveness, either individually or as coordinated immune hubs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the combination of \u03b1PD-1, the class I histone deacetylase inhibitor entinostat, and the IL-15 superagonist N-803 in CPB-resistant murine CRC and breast cancer models with varying antigen presentation deficiencies. Proteomic, transcriptomic, spatial, and functional analyses were completed to identify treatment-specific immune remodeling. Translational relevance was assessed using publicly available CPB-treated cancer genomic datasets and functional assays with patient-derived peripheral blood mononuclear cells (PBMCs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Triple therapy increased stem-like TCF1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in tumor-draining lymph nodes and tumors, concomitant with increased intratumoral cytotoxic GZMB\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Therapeutic efficacy was associated with remodeling of the tumor microenvironment, uniquely marked by enrichment of intratumoral immune niches comprising TCF1\n                      <jats:sup>+<\/jats:sup>\n                      and cytotoxic CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, type 1 conventional dendritic cells, and B cells, along with concerted cytokine and chemokine production. A transcriptional signature derived from triple therapy-induced immune niches predicted favorable clinical responses across multiple CPB-experienced cancer cohorts. These responses were functionally corroborated by increased markers of cytotoxicity in patient-derived PBMCs in vitro.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Treatment with entinostat, N-803, and \u03b1PD-1 boosts anti-tumor intratumoral immune niches comprising TCF1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Collectively, these findings suggest that TCF1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell immune niches previously associated with \u03b1PD-1 responsiveness and lacking in non-responders, including most CRC patients, may be restored by the addition of entinostat and N-803 to \u03b1PD-1 therapy to treat \u03b1PD-1-refractory patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015228","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:15:14Z","timestamp":1789208114000},"page":"e015228","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Epigenetic plus cytokine therapy induces stem-like CD8\n                    <sup>+<\/sup>\n                    T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct00001846","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00179309","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00088413","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7497-9459","authenticated-orcid":false,"given":"Christine Mall","family":"Minnar","sequence":"first","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2608-0673","authenticated-orcid":false,"given":"Asma Sarah","family":"Khelifa","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lui","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E","family":"Lothstein","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-7325","authenticated-orcid":false,"given":"Ainara","family":"Meler","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-2707","authenticated-orcid":false,"given":"Maria del Mar","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9730-8209","authenticated-orcid":false,"given":"Duane H","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9506-372X","authenticated-orcid":false,"given":"Lisa K","family":"Poppe","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Roller","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Canubas","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-3307","authenticated-orcid":false,"given":"George","family":"Zaki","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5742-6982","authenticated-orcid":false,"given":"Wiem","family":"Lassoued","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Lobanov","sequence":"additional","affiliation":[{"name":"CCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Nousome","sequence":"additional","affiliation":[{"name":"CCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Finney","sequence":"additional","affiliation":[{"name":"CCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Cam","sequence":"additional","affiliation":[{"name":"CCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Soon-Shiong","sequence":"additional","affiliation":[{"name":"ImmunityBio, Culver City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-2912","authenticated-orcid":false,"given":"James L","family":"Gulley","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7932-4072","authenticated-orcid":false,"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-8122","authenticated-orcid":false,"given":"Sofia R","family":"Gameiro","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"2026091203150543000_14.9.e015228.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32319-0"},{"key":"2026091203150543000_14.9.e015228.2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ijc.34464","article-title":"How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: from mechanisms to translation","volume":"153","author":"Wang","year":"2023","journal-title":"Intl Journal of Cancer"},{"key":"2026091203150543000_14.9.e015228.3","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-023-00605-4","article-title":"Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer","volume":"9","author":"Borr\u00e0s","year":"2023","journal-title":"Cell Discov"},{"key":"2026091203150543000_14.9.e015228.4","doi-asserted-by":"crossref","first-page":"188623","DOI":"10.1016\/j.bbcan.2021.188623","article-title":"Drug resistance in colorectal cancer: an epigenetic overview","volume":"1876","author":"Luo","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026091203150543000_14.9.e015228.5","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026091203150543000_14.9.e015228.6","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s43018-024-00729-w","article-title":"Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial","volume":"5","author":"Roussos Torres","year":"2024","journal-title":"Nat Cancer"},{"key":"2026091203150543000_14.9.e015228.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3305"},{"key":"2026091203150543000_14.9.e015228.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25393-x","article-title":"Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape","volume":"12","author":"Hicks","year":"2021","journal-title":"Nat Commun"},{"key":"2026091203150543000_14.9.e015228.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0727"},{"key":"2026091203150543000_14.9.e015228.10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004561","article-title":"Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1\/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies","volume":"10","author":"Minnar","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026091203150543000_14.9.e015228.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100594"},{"key":"2026091203150543000_14.9.e015228.12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.3557","article-title":"ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer","volume":"36","author":"Azad","year":"2018","journal-title":"JCO"},{"key":"2026091203150543000_14.9.e015228.13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat Commun"},{"key":"2026091203150543000_14.9.e015228.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02813-1"},{"key":"2026091203150543000_14.9.e015228.15","unstructured":"Clarke H . FDA authorizes expanded access program of Anktiva for lymphopenia. Urology Times 2025;53."},{"key":"2026091203150543000_14.9.e015228.16","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0551-y","article-title":"Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy","volume":"7","author":"Knudson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026091203150543000_14.9.e015228.17","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30148-7"},{"key":"2026091203150543000_14.9.e015228.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.03.015"},{"key":"2026091203150543000_14.9.e015228.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.08.003"},{"key":"2026091203150543000_14.9.e015228.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.08.026"},{"key":"2026091203150543000_14.9.e015228.21","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg7836","article-title":"A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response","volume":"6","author":"Connolly","year":"2021","journal-title":"Sci Immunol"},{"key":"2026091203150543000_14.9.e015228.22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah6499"},{"key":"2026091203150543000_14.9.e015228.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.12.002"},{"key":"2026091203150543000_14.9.e015228.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.06.008"},{"key":"2026091203150543000_14.9.e015228.25","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221985120","article-title":"Characteristics and anatomic location of PD-1(+)TCF1(+) stem-like CD8 T cells in chronic viral infection and cancer","volume":"120","author":"Im","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091203150543000_14.9.e015228.26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1127-7"},{"key":"2026091203150543000_14.9.e015228.27","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4241"},{"key":"2026091203150543000_14.9.e015228.28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164206"},{"key":"2026091203150543000_14.9.e015228.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287733","article-title":"Generation of murine tumor models refractory to \u03b1PD-1\/-L1 therapies due to defects in antigen processing\/presentation or IFN\u03b3 signaling using CRISPR\/Cas9","volume":"19","author":"Chariou","year":"2024","journal-title":"PLoS One"},{"key":"2026091203150543000_14.9.e015228.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-020-0512-1"},{"key":"2026091203150543000_14.9.e015228.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02392-x"},{"key":"2026091203150543000_14.9.e015228.32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-07153-z","article-title":"Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment","volume":"12","author":"Jin","year":"2022","journal-title":"Sci Rep"},{"key":"2026091203150543000_14.9.e015228.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0791-5"},{"key":"2026091203150543000_14.9.e015228.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07524-1"},{"key":"2026091203150543000_14.9.e015228.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.002"},{"key":"2026091203150543000_14.9.e015228.36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41590-025-02388-0","article-title":"BACH2 dosage establishes the hierarchy of stemness and fine-tunes antitumor immunity in CAR T cells","volume":"27","author":"Hu","year":"2026","journal-title":"Nat Immunol"},{"key":"2026091203150543000_14.9.e015228.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-568451"},{"key":"2026091203150543000_14.9.e015228.38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3344"},{"key":"2026091203150543000_14.9.e015228.39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.11.7507"},{"key":"2026091203150543000_14.9.e015228.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-024-01045-4"},{"key":"2026091203150543000_14.9.e015228.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00787-3"},{"key":"2026091203150543000_14.9.e015228.42","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201847517"},{"key":"2026091203150543000_14.9.e015228.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2003.09.006"},{"key":"2026091203150543000_14.9.e015228.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00619-z"},{"key":"2026091203150543000_14.9.e015228.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01792-2"},{"key":"2026091203150543000_14.9.e015228.46","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3556"},{"key":"2026091203150543000_14.9.e015228.47","doi-asserted-by":"crossref","unstructured":"Magen A , Hamon P , Fiaschi N , et al . Data from: intratumoral mregdc and tfr-link niches enable local reinvigoration of cd8 t cells following pd-1 blockade. In: NCBI Gene Expression Omnibus (GEO), GEO206325. 2023. Available: https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE206325","DOI":"10.1136\/jitc-2022-SITC2022.0541"},{"key":"2026091203150543000_14.9.e015228.48","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","article-title":"Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer","volume":"43","author":"Osorio","year":"2025","journal-title":"Cancer Cell"},{"key":"2026091203150543000_14.9.e015228.49","doi-asserted-by":"crossref","DOI":"10.1126\/science.ady1678","article-title":"Dendritic cells control tertiary lymphoid structure development and maintenance in cancer","volume":"393","author":"Mattiuz","year":"2026","journal-title":"Science"},{"key":"2026091203150543000_14.9.e015228.50","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02219-2"},{"key":"2026091203150543000_14.9.e015228.51","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s12015-017-9761-1","article-title":"The regulatory role of IFN-\u03b3 on the proliferation and differentiation of hematopoietic stem and progenitor cells","volume":"13","author":"Qin","year":"2017","journal-title":"Stem Cell Rev Rep"},{"key":"2026091203150543000_14.9.e015228.52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431718"},{"key":"2026091203150543000_14.9.e015228.53","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1158\/1078-0432.CCR-25-1490","article-title":"Increased peripheral T stem cell-like memory features in patients with advanced solid tumors treated with tumor-targeting IL-12 immunocytokine therapy","volume":"31","author":"Goswami","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026091203150543000_14.9.e015228.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1836-5"},{"key":"2026091203150543000_14.9.e015228.55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09754-w"},{"key":"2026091203150543000_14.9.e015228.56","doi-asserted-by":"crossref","unstructured":"Afeyan AB , Nagler A , Tu CR , et al . Tertiary lymphoid structures harbour stem-like tumour-specific T cells. Nature 2026. doi:10.1038\/s41586-026-10808-w","DOI":"10.1038\/s41586-026-10808-w"},{"key":"2026091203150543000_14.9.e015228.57","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:15:19Z","timestamp":1789208119000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,12]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-015228"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015228","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}